In vitro Organic Acid Production and In Vivo Food Pathogen Suppression by Probiotic S. thermophilus and L. bulgaricus

Smith Etareri Evivie1,2†, Amro Abdelazez1,3, Bailiang Li1†, Xin Bian4, Wan Li1, Jincheng Du1, Guicheng Huo1* and Fei Liu1

1 Key Laboratory of Dairy Science, Ministry of Education, College of Food Sciences, Northeast Agricultural University, Harbin, China, 2 Food Science and Nutrition Unit, Department of Animal Science, Faculty of Agriculture, University of Benin, Benin City, Nigeria, 3 Department of Dairy Microbiology, Animal Production Research Institute, Agriculture Research Center, Giza, Egypt, 4 Department of Food Engineering, Harbin University of Commerce, Harbin, China

Foodborne pathogens are a major source of morbidity and mortality worldwide. For this cause, exploring various effective ways of suppressing their spread is at the forefront of many research projects. The current study aims to investigate the in vitro organic acid production of S. thermophilus KLDS 3.1003 and L. bulgaricus KLDS 1.0207 strains, their in vivo suppression of and immuno-modulatory effects against E. coli ATCC 25922 and S. aureus ATCC 25923 pathogens. First, lactic and acetic acid production using three carbon sources – 1% glucose (control), 1% sucrose, and 1% fructo-oligosaccharides (FOS) – was determined by HPLC. For the in vivo section, a total of 40 BALB/c mice were purchased and divided into 10 treatment groups (control and nine treatments). Animals were given 1 week to acclimatize and then fed treatment diets for 14 days. Afterward, hematological (RBC, WBC, HB, PLT, Neutrophils, Eosinophils, Lymphocytes, and Monocytes) and histopathological analyses were carried out. All analyses were done in triplicate. Results show that lactic and acetic acid productions for both strains increased with supplementation and were highest after 1% FOS addition. Regardless of carbon source, L. bulgaricus KLDS 1.0207 produced higher \((P < 0.05)\) amounts of lactic and acetic acids than S. thermophilus KLDS 3.1003. Also, generally better hematological parameters in probiotic groups than the control \((P < 0.05)\) were observed. In some instances, mice in probiotic treatment groups had better immunity levels (lymphocytes, monocytes, neutrophils, eosinophils) than those in the control and pathogen groups. Histopathological studies showed that no anomalies were associated with S. thermophilus KLDS 3.1003 and L. bulgaricus KLDS 1.0207 administration. In conclusion, S. thermophilus KLDS 3.1003 and L. bulgaricus KLDS 1.0207 strains are not only probiotic candidates but can have therapeutic applications.

Keywords: S. thermophilus, L. bulgaricus, probiotics, foodborne pathogens, immunity, organic acid
INTRODUCTION

Nutritious foods sustain the complex requirements of the human organism, compensating the limitations of our digestive physiology and anabolic restrictions. Foods are also the perfect media for the growth of microorganisms rendering them inedible and even dangerous for consumption. It has been an everlasting struggle for humans to keep food safe and wholesome (Papadimitrour et al., 2015). Functional food acts as beneficial compounds or foods containing microorganisms exhibiting a pivotal role in strengthening and enriching health well-being and suppressing some strict disease, for instance, obesity, diabetes, atherosclerosis, heart disease, retinopathy, kidney toxicity, atherosclerosis, hypertension, diabetic foot ulcers, and cystic fibrosis (Ji et al., 2015; Abdelazez et al., 2017). Many lactic acid bacteria (LAB) strains serve as probiotics in functional foods.

Annually, it is estimated that as many as 30% of people in the industrialized countries suffer from foodborne illnesses (Ghanbari et al., 2013). Foodborne illnesses can spread in several forms from farm to fork so the importance of good management practices cannot be overemphasized (Hoffmann et al., 2017). The antagonistic effects of L. helveticus KLDS 1.8701 on some notable foodborne pathogens was recently reported but other promising LAB strains require more detailed studies (Bian et al., 2015). Next-generation sequencing (NGS) is one genomic tool that can be used to enhance the increased inhibition of notable foodborne pathogens by LAB (Didelot et al., 2012). Detailed studies of the various components, functionalities and potential uses of many beneficial LAB have been made possible by NGS (Lecomte et al., 2016; Landete, 2017).

The human intestinal ecosystem is one of the most densely populated and highly diverse microbial environment known to date, composed of stable and variable microbial groups. These microbes therein provide us with a significant metabolic potential encoded in the metagenome; thus the intestinal microbiota has been postulated as another organ of the human body (Sánchez et al., 2017). Thanks to NGS, it is now known that aberrant microbiota profiles have been found in highly prevalent diseases, such as inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) or colorectal cancer, among others (Gevers et al., 2014; Bullman et al., 2017; Bennet et al., 2018). Purported associations between gut microbiota composition and human health have resulted in the use of LAB as functional food ingredients (Arboley et al., 2016). LAB colonization of the gut microbiota is believed to support appropriate immune development and prevent/limit the onset of certain gut diseases (Garcia-Mantrana et al., 2018). Many LABs can be used as probiotics to modulate the structure of the host gut microbiota, thus increasing their functionalities (Evivie et al., 2017; Li et al., 2017b).

Although a number of in vitro studies have been reported to show clearer correlation between immunity parameters and diet supplemented with some notable LAB strains (Evivie et al., 2017; Li et al., 2017b, 2018), more in vivo investigations are still required to validate these findings. Again, given the global deleterious impact of foodborne pathogens, a number of research initiatives are currently exploring ways of significantly lowering their effect which will improve healthy living. In the present study, two potential probiotic strains, S. thermophilus KLDS 3.1003 and L. bulgaricus KLDS 1.0207 were first evaluated for lactic and acetic acid production levels using different carbon sources in vitro. Afterward pathogens and probiotic bacteria were orally administered to 40 BALB/c mice in an in vivo trial where hematological and histological analyses were carried out. It is anticipated that the findings of this study would give further insights in the use of these strains as probiotics as well as show that immunity parameters of the study animals improved with LAB supplementation.

MATERIALS AND METHODS

Bacteria Strains and Growth Conditions

Streptococcus thermophilus KLDS 3.1003 and Lactobacillus bulgaricus KLDS 1.0207 were obtained from the Key laboratory of Dairy Science (KLDS), Northeast Agricultural University, China. E coli ATCC 25922 and S. aureus ATCC 25923 were obtained from the Heilongjiang Entry-Exit Inspection and Quarantine Bureau, China. Pathogens were incubated as described by Bian et al. (2015). All chemicals and reagents used in this research were obtained from reliable suppliers in Harbin, China and of analytical grade.

Effect of Carbon Sources on the Lactic and Acetic Acid Production of Bacterial Strains

This was carried out as described by Bian et al. (2015) with modifications. Briefly, glucose, sucrose, and fructooligosaccharide (FOS) (1% each) served as supplementary carbon sources to the M17 and mMRS broths with 1% glucose (control). Cell-free supernatants (CFS) were prepared as previously described. Lactic and acetic acid production of the different CFS samples were determined by High-Performance Liquid Chromatography (HPLC) as previously described by Zhang et al. (2011) with some modifications. Acid separation was achieved using an AMINEX HPX-87H ion exchange column (Bio-Rad Labs, Berkeley, CA, United States) and the organic acids were detected using a differential refraction detector with 5 mM H2SO4. Acid identification was carried out by comparing the retention times of the samples with that of the standards for organic acids. Experiments were carried out in triplicate.

Animals

For the in vivo phase of this research, 40 female BALB/c mice (8 weeks old, weighing 15–25 g) were purchased from the Vital River Laboratory Animal Technology Company (Beijing, China). Feed and water were provided ad libitum in the first week of arrival. Afterward, 10 steel cages with eating and drinking sections were used to house the 10 treatment groups (4 mice/group). Each group was fed one diet throughout the study period of 14 days. The diets are as follows – Control (0.5% saline solution), TST (S. thermophilus KLDS 3.1003 only), TLB (L. bulgaricus KLDS 1.0207 only),
**Hematological Analyses**

After 14 days of feeding (excluding 1 week of acclimatization), all mice were fasted and sacrificed humanely. Blood samples were collected in heparinized tubes and assessed for red blood cell count (RBC), white blood cell count (WBC), hemoglobin (HB), platelet count (PLT), neutrophils, lymphocytes, monocytes, and eosinophils using the automatic hematological analyzer (Nihon Kohden, Tokyo, Japan).

**RESULTS**

**Lactic and Acetic Acid Production Profiles of Probiotic LABs**

*S. thermophilus* KLDS 3.1003 and *L. bulgaricus* KLDS 1.0207 showed increased production of lactic and acetic acids when the M17 and MRS media were supplemented in the following increasing order: 1% glucose, 1% sucrose, and 1% FOS (Tables 1, 2). Acetic acid production was significantly (*P* < 0.05) lower than lactic acid production for both strains, though this improved slightly with supplemented glucose, sucrose, and FOS. *S. thermophilus* KLDS 3.1003 had its highest lactic acid production in the FOS-supplemented medium (23.31 ± 0.14 mg mL⁻¹). This yield was significantly higher (*P < 0.05*) from that of the control (4.66 ± 0.09 mg mL⁻¹) and 1% glucose medium (11.49 ± 0.22 mg mL⁻¹). Lactic acid production between both strains was significantly different (*P < 0.05*). *S. thermophilus* KLDS 3.1003 also had its highest acetic acid production using the FOS-supplemented media (9.05 ± 0.06 mg mL⁻¹). *L. bulgaricus* KLDS 1.0207 yielded more lactic (38.96 ± 0.06 mg mL⁻¹) and acetic (11.77 ± 0.18 mg mL⁻¹) acids than *S. thermophilus* KLDS 3.1003 and also had highest acid production levels after 1% FOS addition (*P < 0.05*). Genes for carbohydrate fermentation and additional genomic properties are also reported in this study (see Supplementary Figures S1, S2).

**Hematological Analyses**

Hematological parameters of experimental animals in the control, T_{ST}, T_{STLB}, T_{STEC}, and T_{STSA} groups are as shown in Table 3. For the WBC (10⁹ /µL), the T_{STLB}, T_{ST}, and C groups were 10.95, 10.77, and 10.80, respectively. The % lymphocytes in the above order were 74.83, 72.46, and 71.70, respectively. The general trend was that combined or single strain treatments gave superior performances compared to the Control. With the oral administration of pathogen alongside *S. thermophilus* KLDS 3.1003, there was no marked difference between the readings obtained. In RBC for example, the C, T_{ST}, and T_{STSA} groups gave readings (expressed as ×10⁹/µL) of 6.85, 6.51, and 6.73, respectively. For the T_{ST}, there readings were 6.85, 6.38, and 6.51, respectively. For the RBC, PLT, lymphocytes, monocytes, neutrophils and eosinophils parameters, T_{STLB}-fed experimental animals had significantly (*P < 0.05*) higher values than both the T_{ST} and C groups. With the exception of HB, T_{LBEC} readings were generally better than T_{EC} (*P < 0.05*). Also, all T_{STSA} values were significantly higher than T_{SA} group, suggesting that *L. bulgaricus* KLDS 1.0207 significantly inhibited *S. aureus* in vivo (Table 4).

**TABLE 1** | Effect of carbon source on lactic acid production of *S. thermophilus* KLDS 3.1003 and *L. bulgaricus* KLDS 1.0207.

| LAB strains | Control | 1% Glucose | 1% Sucrose | 1% FOS |
|-------------|---------|------------|------------|--------|
| *S. thermophilus* KLDS 3.1003 | 4.66 ± 0.09b | 9.05 ± 0.06b | 15.27 ± 0.20b | 23.31 ± 0.14b |
| *L. bulgaricus* KLDS 1.0207 | 25.23 ± 0.33a | 30.88 ± 0.17a | 33.30 ± 0.25a | 38.96 ± 0.06a |

All values (expressed as mean ± SD) were obtained from three independent experiments. Values with same alphabets along column are not significantly different (*P > 0.05*).

**TABLE 2** | Effect of carbon source on acetic acid production of *S. thermophilus* KLDS 3.1003 and *L. bulgaricus* KLDS 1.0207.

| LAB strains | Control | 1% Glucose | 1% Sucrose | 1% FOS |
|-------------|---------|------------|------------|--------|
| *S. thermophilus* KLDS 3.1003 | 0.31 ± 0.02b | 1.04 ± 0.11b | 2.83 ± 0.03b | 4.82 ± 0.07b |
| *L. bulgaricus* KLDS 1.0207 | 1.48 ± 0.02a | 3.25 ± 0.10a | 6.98 ± 0.09a | 11.77 ± 0.17a |

All values (expressed as mean ± SD) were obtained from three independent experiments. Values with same alphabets along column are not significantly different (*P > 0.05*).
**TABLE 3** Hematological parameters of study animals after oral administration of *S. thermophilus* KLDS 3.1003 for 14 days.

| Parameters          | Control  | TST | TSTLB | TEC | TSA | TSTEC | TSTSA |
|---------------------|----------|-----|-------|-----|-----|-------|-------|
| RBC (x10³ /µL)     | 6.85 ± 0.08b | 6.90 ± 0.04b | 7.06 ± 0.05a | 6.51 ± 0.04d | 6.38 ± 0.05e | 6.73 ± 0.05c | 6.51 ± 0.06d |
| WBC (x10³ /µL)     | 10.80 ± 0.10a | 10.77 ± 0.12b | 10.95 ± 0.06a | 10.81 ± 0.09a | 10.44 ± 0.06c | 10.73 ± 0.04b | 10.51 ± 0.10c |
| HB (g/L)            | 138.29 ± 0.57a | 138.46 ± 0.49a | 139.70 ± 0.53a | 136.58 ± 0.47c | 136.03 ± 0.21c | 137.31 ± 0.31b | 137.97 ± 0.16b |
| PLT (x10³ /µL)     | 1215.57 ± 6.32b | 1215.48 ± 6.03b | 1231.87 ± 4.68a | 1200.89 ± 5.06d | 1199.15 ± 7.40d | 1209.14 ± 8.16c | 1201.69 ± 5.64d |
| Neutrophils (%)     | 23.05 ± 0.42b | 23.79 ± 0.23a | 23.79 ± 0.20a | 22.49 ± 0.09c | 23.34 ± 0.13c | 23.19 ± 0.22b | 22.80 ± 0.05c |
| Lymphocytes (%)     | 71.70 ± 0.97b | 72.46 ± 0.32b | 74.83 ± 0.27a | 70.39 ± 0.59a | 71.10 ± 0.10c | 71.33 ± 0.32c | 71.28 ± 0.29c |
| Monocytes (%)       | 5.11 ± 0.18b | 5.34 ± 0.03b | 6.05 ± 0.08a | 4.75 ± 0.06c | 4.69 ± 0.03c | 4.98 ± 0.06b | 4.77 ± 0.06c |
| Eosinophils (%)     | 1.27 ± 0.07b | 1.31 ± 0.02b | 1.45 ± 0.07a | 1.19 ± 0.01c | 1.18 ± 0.02d | 1.22 ± 0.02c | 1.19 ± 0.01c |

Values are expressed as Mean ± SD, Control, sterile normal saline; RBC, red blood cell count; WBC, white blood cell count; HB, hemoglobin; PLT, platelet count. Values with the same alphabet along the same row are not significantly different (P > 0.05).

**TABLE 4** Hematological Parameters of Study animals after oral administration of *L. bulgaricus* KLDS 1.0207 for 14 days.

| Parameters          | Control  | TLB  | TSTLB | TEC  | TSA  | TSTEB | TSTSA |
|---------------------|----------|------|-------|------|------|-------|-------|
| RBC (x10³ /µL)     | 6.85 ± 0.08b | 6.99 ± 0.08a | 7.06 ± 0.05a | 6.51 ± 0.04d | 6.38 ± 0.05e | 6.73 ± 0.05c | 6.51 ± 0.06d |
| WBC (x10³ /µL)     | 10.80 ± 0.10a | 10.97 ± 0.07a | 10.95 ± 0.06a | 10.81 ± 0.09a | 10.44 ± 0.06c | 10.73 ± 0.04b | 10.51 ± 0.10c |
| HB (g/L)            | 138.29 ± 0.57a | 138.95 ± 0.60a | 139.70 ± 0.53a | 136.58 ± 0.47c | 136.03 ± 0.21c | 137.31 ± 0.31b | 137.97 ± 0.16b |
| PLT (x10³ /µL)     | 1215.57 ± 6.32b | 1215.48 ± 6.03b | 1231.87 ± 4.68a | 1200.89 ± 5.06d | 1199.15 ± 7.40d | 1209.14 ± 8.16c | 1201.69 ± 5.64d |
| Neutrophils (%)     | 23.05 ± 0.42b | 23.79 ± 0.23a | 23.79 ± 0.20a | 22.49 ± 0.09c | 23.34 ± 0.13c | 23.19 ± 0.22b | 22.80 ± 0.05c |
| Lymphocytes (%)     | 71.70 ± 0.97b | 72.46 ± 0.32b | 74.83 ± 0.27a | 70.39 ± 0.59a | 71.10 ± 0.10c | 71.33 ± 0.32c | 71.28 ± 0.29c |
| Monocytes (%)       | 5.11 ± 0.18b | 5.34 ± 0.03b | 6.05 ± 0.08a | 4.75 ± 0.06c | 4.69 ± 0.03c | 4.98 ± 0.06b | 4.77 ± 0.06c |
| Eosinophils (%)     | 1.27 ± 0.07b | 1.31 ± 0.02b | 1.45 ± 0.07a | 1.19 ± 0.01c | 1.18 ± 0.02d | 1.22 ± 0.02c | 1.19 ± 0.01c |

Values are expressed as Mean ± SD, Control, sterile normal saline; RBC, red blood cell count; WBC, white blood cell count; HB, hemoglobin; PLT, platelet count. Values with the same alphabet along the same row are not significantly different (P > 0.05).

**Histopathology and Necropsy Analyses**

At the end of the 14-day *in vivo* study, gross necropsy and histopathological examination of BALB/c mice were carried out. Results show that no organ damages were detected in mice of all the groups (Figures 1–3). Although the pathogen and LAB-pathogen groups showed no signs of damage, we recorded some mortality at the 7th and 14th day of this study. From the micrographs, no histopathological abnormalities were related to *S. thermophilus* KLDS 3.1003 and *L. bulgaricus* KLDS 1.0207 administration were observed.

**DISCUSSION**

**Supplementary Carbon Sources on Lactic and Acetic Acid Production**

Organic acids are important pathogen-inhibiting compounds secreted by LAB (Vieco-Saiz et al., 2019). Results from this study showed that *L. bulgaricus* KLDS 1.0207 produced significantly higher amounts of lactic and acetic acids than *S. thermophilus* KLDS 3.1003. Although we had recently investigated the organic acid production of *L. helveticus* KLDS 1.8701 based on different carbon sources used, specific organic acids were not elucidated (Bian et al., 2015). The present study not only investigates more strains but also specific organic acid production levels (lactic and acetic). In a quantitative HPLC study by Gezginc et al. (2015), much higher yields of lactic acid by *S. thermophilus* (0–77.9 mg kg⁻¹) and *L. bulgaricus* (0–103.5 mg kg⁻¹) strains isolated from Turkish yogurts were obtained, both studies agree that organic acid production are both strain and species-specific. This is further corroborated by a recent study showing the production of six different organic acids by LAB using fish infusion broth (Özcelik et al., 2016). Moreover, the present study reports significant increase in the lactic and acetic acid yields in the following order: 1% FOS > 1% sucrose > 1% glucose, suggesting that the nature of the growth medium plays a critical role in organic acid production by probiotics. FOS has been shown to not only enhance the antagonistic potentials of LAB strains but is also a more efficient carbon source than glucose (Tejero-Sariñena et al., 2012; Bian et al., 2015; Kim et al., 2019). Furthermore as a prebiotic, it has been shown to stimulate the growth of probiotic LABs and thus increase their antagonistic effects on pathogenic organisms, primarily by enhancing the production of organic acids (lactic, acetic, propionic, and butyric) as well as a significant decrease in the pH of the fermented broth (Yang et al., 2011; Tejero-Sariñena et al., 2012; He et al., 2016). The development of effective symbiotics based on these findings thus merits further studies as this is more synergistic that individual effects of probiotics and prebiotics (Evivie, 2013; Evivie et al., 2017).
Effects of Probiotic Administration on Hematological Parameters

Dietary components play a critical role either in the spread or treatment of a number of health disorders. As such, they remain a key area of research interest (Xu et al., 2015; Al-muzafar and Amin, 2017). In addition, in vivo animal studies are important because the body functioning of animals is in many instances, similar to that of humans (Shokryazdan et al., 2016). Although the potential antibiotic and probiotic properties of these and other selected LAB strains have been earlier reported, the present study further assessed their pathogen-inhibiting roles in vivo. Both S. thermophilus KLDS 3.1003 and L. bulgaricus KLDS 1.0207 significantly suppressed the pathogenicity of E. coli ATCC 25922 and S. aureus ATCC 25923. Also, there was no significant difference between the control and treatment (T_{LB}, T_{STLB}, T_{STEC}, T_{LBEC}, T_{STSA}, and T_{LBSA}) groups. The parameters assessed are also used to measure the standard of immunity, therefore this study compared the immune-responses of animals in the control group with those in the various treatment groups. The neutrophils, lymphocytes, monocytes, and eosinophil levels in the T_{ST} group were 23.60, 73.68, 6.27, and 1.44, respectively. For the same parameters, the C values were 23.05, 71.70, 5.11, and 1.27, respectively. Interestingly, even in the T_{ST}, T_{STEC}, T_{LBEC}, T_{STSA}, and T_{LBSA} groups, the standard of immunity were still higher than the control group. These imply that single and co-culture doses of S. thermophilus KLDS 3.1003 and L. bulgaricus KLDS 1.0207 can potentially improve immunity levels in humans. It has also been recently shown that L. helveticus KLDS 1.8701 can raise immunity standards following pathogenic E. coli 0157:H7 infection in mice (Bian et al., 2016). No significant differences (P > 0.05) between the control and experimental groups were observed in the present study. Furthermore, food containing probiotics improves IgA and other immunity parameters (Aboderin and Oyetayo, 2006; Shokryazdan et al., 2016). Niamah et al. (2017) also confirmed not only improvements in hematological criteria of experimental mice but also in the standard of immunity. These
Evivie et al. Applications of Lactic Acid Bacteria

**FIGURE 2** Representative photomicrographs of organs of mice fed Control, T_{SA}, T_{STSA}, and T_{LBSA} diets 1A–1D: Control (Kidney, liver, lung, and spleen, respectively), 5A–5D: T_{SA} (Kidney, liver, lung, and spleen, respectively), 6A–6D: T_{STSA} (Kidney, liver, lung, and spleen, respectively), and 7A–7D: T_{LBSA} (Kidney, liver, lung, and spleen, respectively).

Recent in vivo findings as well as the present study confirm that beneficial bacteria strains can be potential ingredients in food formulations in view of improving health and wellbeing. From the T_{STLB} results obtained, it is suggestive that a co-culture of *S. thermophilus* KLDS 3.1003 and *L. bulgaricus* KLDS 1.0207 may be more effective than individual strains. In treating metabolic syndrome (MS) in high-fat diet (HFD)-fed rats, Wang et al. (2015) postulated that a combination of individual strains may be a more effective treatment than single-strain doses. Recent findings showing that yogurt cultures of *S. thermophilus* and *L. bulgaricus* can modulate immune responses to improve some gut microbiota dysfunctions, are also in consonance with the present study (Usui et al., 2019; Wasilewska et al., 2019). Further studies of this co-culture in suppressing the growth of other pathogens are thus warranted. The general trend of values obtained were in consonance with our previous findings that *S. thermophilus* KLDS 3.1003 was less effective against *S. aureus* than *E. coli*. RBC, WBC, HB, and PLT values for the T_{LB}-fed animals were 6.99, 10.97, 139.95, and 1238.14, respectively. These values were far better than both T_{ST} and C. T_{LBEC} and T_{LBSA}-fed animals generally had superior performance to T_{STEC} and T_{STSA}-fed animals in terms of hematological results. These may be attributed to strain differences and specificity as a preliminary in vitro trial showed that that the CFS of *L. bulgaricus* KLDS 1.0207 had more antimicrobial effects against *S. aureus* ATCC 25923 and *E. coli* ATCC 25922 than *S. thermophilus* KLDS 3.1003 (data not shown).

**Effects of Probiotic Administration on Histopathological Analyses**

Apart from their immune-modulatory effects, it has been suggested that probiotics have an effect on the gut microbiome by their antimicrobial activities directed toward intestinal pathogens (Rioux et al., 2005). Results from this study show that there were no signs of organs damage in all study animals. Histopathology can provide clear clinical advantage, *S. thermophilus* KLDS 3.1003 and/or *L. bulgaricus* KLDS 1.0207
intake did not result in any histologic abnormalities. This, to our knowledge, is the first study elucidating the histopathological evidence of non-inflammation of these two LAB strains. The oral administration of low (1 × 10^9 CFU/kg BW) and high (1 × 10^10 CFU/kg BW) doses of *L helveticus* KLDS 1.8701 did not give histological or clinical signs suggestive of organ damage (Li et al., 2017a). Probiotic therapy is becoming increasingly popular in veterinary medicine, and has been recommended for the treatment or prevention of a variety of gastrointestinal disorders. However, few objective studies attesting clinical efficacy of probiotics are available (Chang et al., 2018). In a recent study using dogs with idiopathic IBD, Rossi et al. (2014) reported that probiotics treatment (VSL#3) lowered histopathological scores compared to a combined treatment of prednisone and metronidazole. These researchers also noted that the probiotic-treated specifically conferred protection associated with an enhancement of regulatory T-cell markers (FoxP3+ and TGF-b+) and not in animals receiving combination therapy. Also, Al-muzafar and Amin (2017) showed that probiotics not only ameliorated the effects of high-fat sucrose diet (HFSD) in male albino rats, but the HFSD + probiotics group also showed improved lipid profiles, better leptin and resistin levels, and better TNF-α and IL-6 levels than the HFSD-only group. There were no histopathological signs of non-alcoholic fatty liver disease (NAFLD) in the HFSD + probiotic group which is in consonance with the findings of the present study.

**CONCLUSION**

Foodborne pathogens are significantly deleterious to normal body functioning and researchers are currently investigating novel and effective ways mitigating their impact. The *in vitro* and *in vivo* suppression of *S. aureus* ATCC 25923 and *E. coli* ATCC 25922 by *S. thermophilus* KLDS 3.1003 and *L. bulgaricus* KLDS 1.0207 were investigated in this report. Lactic and acetic acid productions increased with supplementation with *L. bulgaricus* KLDS 1.0207 being significantly higher than *S. thermophilus* KLDS 1.0207 (P < 0.05). Hematological and serum biochemical parameters generally improved in animals fed LAB-treated diets, and in some instances, TSTLB-fed animals fared better than TST
and TLR-fed ones. No histological damages were observed in the organs in the control or treatment groups. For all in vitro and most of the in vivo parameters studied, results for L. bulgaricus KLDS 1.0207 were better than S. thermophilus KLDS 3.1003. In all, both strains can be adjudged good probiotic candidates and can have further therapeutic applications.

**DATA AVAILABILITY**

The datasets generated for this study can be found in National Center for Biotechnology Information, CP016877.

**ETHICS STATEMENT**

This study was carried out in accordance with the recommendations of "the Institutional Animal Use and Care Committee of the Northeast Agricultural University." The protocol was approved by the above-mentioned committee "under the approved protocol number Specific pathogen-free rodent management (SRM)-06."

**AUTHOR CONTRIBUTIONS**

SE and GH conceptualized the study. SE and AA developed the methodology. SE, AA, BL, and XB carried out the experiments.

**REFERENCES**

Abdelazez, A., Muhammad, Z., and Zhang, Q. X. (2017). Production of a functional frozen yogurt fortified with bifidobacterium spp. *BioMed. Res. Int.* 2017:6438528. doi: 10.1155/2018/7356173

Aboderin, S. I., and Oyetayo, V. O. (2006). Haematological studies of rats fed different doses of probiotic, *Lactobacillus plantarum*, isolated from fermenting corn slurry. *Pak. J. Nutr.* 5, 102–105. doi: 10.3923/pjn.2006.102.105

Al-muzafar, H. M., and Amin, K. A. (2017). Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. *BMC Complement. Altern. Med.* 17:43. doi: 10.1186/s12906-016-1540-z

Arboleya, S., Watkins, C., Stanton, C., and Ross, R. P. (2016). Gut bifidobacteria populations in human health and aging. *Front. Microbiol.* 7:1204. doi: 10.3389/fmicb.2016.01204

Bennet, S. M. P., Böhn, L., Störsrud, S., Liljebo, T., Collin, L., Lindfors, P., et al. (2018). Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. *Gut* 67, 872–881. doi: 10.1136/gutjnl-2016-313128

Bian, X., Evivie, S. E., Muhammad, Z., Luo, G. W., Liang, H. Z., Wang, N. N., et al. (2015). *In vitro* assessment of antimicrobial potentials of *Lactobacillus helveticus* strains isolated from traditional cheese in Sinkiang China against food-borne pathogens. *Food Funct.* 7, 789–797. doi: 10.1039/C5FO01041A

Bian, X., Wang, T. T., Xu, M., Evivie, S. E., Luo, G. W., Liang, H. Z., et al. (2016). Effect of *Lactobacillus* strains on intestinal microflora and mucosa immunity in *Escherichia coli* O157: H7-induced diarrhea in mice. *Carr. Microbiol. Microbiol.* 73, 65–70. doi: 10.1007/00284-016-1010-3

Bullman, S., Pedamallu, C. S., Sicinska, E., Clancy, T. E., Zhang, X., Cai, D., et al. (2017). Analysis of fusobacterium persistence and antibiotic response in colorectal cancer. *Science* 358, 1443–1448. doi: 10.1126/science.aal5240

Chang, C. W., Liu, C. Y., Lee, H. C., Huang, Y. H., Lee, L. H., Chiang Chiau, J. S., et al. (2018). *Lactobacillus casei* variety rhamnosus probiotic prevents 5-Fluorouracil/Oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model. *Front. Microbiol.* 9:983. doi: 10.3389/fmicb.2018.00983

Dideolt, B., Rowden, R., Wilson, D. J., Petro, T. E., and Crook, D. W. (2012). Transforming clinical microbiology with bacterial genome sequencing. *Nat. Rev. Genet.* 13, 601–612. doi: 10.1038/nrg3226

Evivie, S. E. (2013). Preliminary studies on pharmaceutical microencapsulation for symbiotic application. *J. Appl. Nat. Sci.* 5, 488–496. doi: 10.3108/jans.v5i2.358

Evivie, S. E., Huo, G. C., Igiene, J. O., and Bian, X. (2017). Some current applications, limitations and future perspectives of lactic acid bacteria as probiotics. *Food Nutr. Res.* 61:1318034. doi: 10.1080/16546628.2017.1318034

García-Mantrana, I., Selma-Royo, M., Alcantara, C., and Collado, M. C. (2018). Shifts on gut microbiota associated to Mediterranean diet adherence and specific dietary intakes on general adult population. *Front. Microbiol.* 9:890. doi: 10.3389/fmicb.2018.00890

Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., et al. (2014). The treatment-naïve microbiome in new-onset Crohn’s disease. *Cell Host Microbe* 15, 382–392. doi: 10.1016/j.chom.2014.02.005

Gezinc, Y., Topcal, F., Comertpay, S., and Akyol, A. (2015). Quantitative assessment of the lactic acid and acetydehyde produced by *Streptococcus thermophilus* and *Lactobacillus bulgaricus* strains isolated from traditional Turkish yogurt using *HPLC*. *J. Dairy Sci.* 98, 1426–1434. doi: 10.3168/jds.2014-8447

Ghanbari, M., Jami, M., Kneifel, W., and Domig, K. J. (2013). Antimicrobial activity and partial characterization of bacteriocins produced by *lactobacilli* isolated from sturgeon fish. *Food Control* 32, 379–385. doi: 10.1016/j.foodcont.2012.12.024

He, S., Wang, X., Zhang, Y., Wang, J., Sun, H., Wang, J., et al. (2016). Isolation and prebiotic activity of water-soluble polysaccharides fractions from the bamboo shoots (Phyllostachys praecox). *Carbohy. Polym.* 151, 295–304. doi: 10.1016/j.carbpol.2016.05.072

Hoffmann, S., Develerschauwer, B., Aspinall, W., Cooke, R., Corrigan, T., Havelaar, A., et al. (2017). Attribution of global foodborne disease to specific foods: findings from a world health organization structured expert elicitation. *PLoS One* 12:e0183641. doi: 10.1371/journal.pone.0183641

**SUPPLEMENTARY MATERIAL**

The Supplemental Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2019.00782/full#supplementary-material
Ji, K., Jang, N. Y., and Kim, Y. T. (2015). Isolation of lactic acid bacteria showing antioxidative and probiotic activities from kimchi and infant feces. J. Microbiol. Biotechnol. 25, 1568-1577. doi: 10.4104/jmb.1501.01077

Kim, S. A., Jang, M. I., Kim, S. Y., Yang, Y., Pavlidis, H. O., and Riche, S. C. (2019). Potential for prebiotics as feed additives to limit foodborne campylobacter establishment in the poultry gastrointestinal tract. Front. Microbiol. 10:91. doi: 10.3389/fmicb.2019.00091

Landete, J. M. (2017). A review of food-grade vectors in lactic acid bacteria: from the laboratory to their application. Crit. Rev. Food Sci. Nutr. 57, 396-416. doi: 10.1080/10408398.2015.1024498

Lecomte, X., Gagnaire, V., Lortal, S., Dary, A., and Genay, M. (2016). Lactic acid bacteria: a review of food-grade vectors in lactic acid bacteria: from the laboratory to their application. J. Dairy Sci. 99, 9343-9357. doi: 10.3168/jds.2016-10849

Li, B., Jin, D., Evivie, S. E., Li, N., Yan, F., Zhao, L., et al. (2017a). Safety assessment of Lactobacillus helveticus KLDS1.8701 based on whole genome sequencing and oral toxicity studies. Toxins 9:301. doi: 10.3390/toxins9030301

Li, B., Jin, D., Evivie, S. E., Li, N., Yan, F., Zhao, L., et al. (2017b). Safety assessment of Lactobacillus helveticus KLDS1.8701 based on whole genome sequencing and oral toxicity studies. Toxins 9:301. doi: 10.3390/toxins9030301

Özcelik, S., Kuley, E., and Ozogul, F. (2016). Formation of lactic, acetic, succinic, propionic, formic and butyric acid by lactic acid bacteria. LWT-FoodSci. Technol. 73, 536-542. doi: 10.1016/j.lwt.2016.06.066

Papadimitrou, K., Pot, B., and Tsakalidou, E. (2015). How microbes adapt to a diversity of food niches. Curr. Opin. Food Sci. 2, 29-35. doi: 10.1016/j.cofs.2015.01.001

Riou, K. P., Madsen, K. L., and Fedorak, R. N. (2005). The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. Gastroenterol. Clin. North Am. 34, 465-482. doi: 10.1016/j.gtc.2005.05.005

Rossi, G., Pengo, G., Caldin, M., Piccionello, A. P., Steiner, J. M., Cohen, N. D., et al. (2014). Comparison of microbial, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. PloS One 9:e94699. doi: 10.1371/journal.pone.0094699

Sánchez, B., Delgado, S., Blanco-Míguez, A., Lourenço, A., Gueimonde, M., and Margolles, A. (2017). Probiotics, gut microbiota, and their influence on host health and disease. Mol. Nutr. Food Res. 61, 1600240. doi: 10.1002/mnfr.201600240

Shokryazdan, P., Jahromi, M. F., Liang, J. B., Kalavathy, R., Sree, C. C., and Ho, Y. W. (2016). Safety assessment of two new Lactobacillus strains as probiotic for human using a rat model. PloS One 11:e0159851. doi: 10.1371/journal.pone.0159851

Tejero-Saritena, S., Barlow, J., Costabile, A., Gibson, G. R., and Rowland, I. (2012). In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids. Anaerobe 18, 530-538. doi: 10.1016/j.anaerobe.2012.08.004

Usui, Y., Kimura, Y., Sato, T., Takemura, N., Ouchi, Y., Ohmiya, H., et al. (2019). Effects of long-term intake of a yogurt fermented with Lactobacillus delbrueckii subsp. bulgaricus KLDS1.8701 and Streptococcus thermophilus 1131 on mice. Int. Immunol. 30, 319-331. doi: 10.1093/intimm/dxy035

Vieco-Saiz, N., Belguessa, Y., Raspoet, R., Auclair, E., Gancel, F., Kempf, I., et al. (2019). Benefits and inputs from lactic acid bacteria and their bacteriocins as alternatives to antibiotic growth promoters during food-animal production. Front. Microbiol. 10:57. doi: 10.3389/fmicb.2019.00057

Wang, J., Tang, H., Zhang, C., Zhao, Y., Derrien, M., Rocher, E., et al. (2015). Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 9, 1-15. doi: 10.1038/ismej.2014.99

Wasilewska, E., Zlotkowska, D., and Wroblewska, B. (2019). Yogurt starter cultures of Streptococcus thermophilus and Lactobacillus bulgaricus ameliorate symptoms and modulate the immune response in a mouse model of dextran sulfate sodium-induced colitis. J. Dairy Sci. 102, 37-53. doi: 10.3168/jds.2018-14520

Xu, J., Lian, F., Zhao, L., Zhao, Y., Chen, X., Zhang, X., et al. (2015). Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J. 9, 552-562. doi: 10.1038/ismej.2014.177

Yang, B., Prasad, K. N., Xie, H., Lin, S., and Jiang, Y. (2011). Structural characteristics of oligosaccharides from soy sauce lees and their potential prebiotic effect on lactic acid bacteria. Food Chem. 126, 590-594. doi: 10.1016/j.foodchem.2010.11.048

Zhang, Y., Zhang, F., Lu, M., Yi, H., Guo, C., Tuo, Y., et al. (2019). Antimicrobial activity against Shigella sonnei and probiotic properties of wild lactobacilli from fermented food. Microbiol. Res. 167, 27-31. doi: 10.1016/j.micres.2011.02.006

Conflicts of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Evivie, Abdelazez, Li, Bian, Li, Du, Huo and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.